TELA Bio Inc TELA
📋 Company Profile
| Industry | Health Care |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2019-11-08 |
| Shares Out. | 44,770,000 |
| Website | telabio.com/ ↗ |
| Phone | 13026587581 |
| Employees | 218 |
| Revenue | $19.1M |
| Gross Profit | $12.5M |
| Net Income | -$12.3M |
| Free Cash Flow | -$30.2M |
| Total Assets | $69.9M |
| Total Liabilities | $75.1M |
| Equity | -$5.2M |
About TELA Bio Inc
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
TELA Bio Inc is a publicly traded company under the ticker symbol TELA on the NASDAQ NMS - GLOBAL MARKET, operating in the Health Care industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)